{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-135310","form_type":"8-K/A","ticker":"WW","cik":"0000105319","company_name":"WW INTERNATIONAL, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.057564+00:00","generated_at":"2026-06-02T04:41:33.071342+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"WW International corrects Q1 subscriber metrics; Clinical subscribers overstated by 4k","bullets":["Clinical End of Period Subscribers corrected to 87k from 91k; Total End of Period Subscribers to 4.004M from 4.008M.","Clinical Paid Weeks corrected to 1.038M from 1.056M; Total Paid Weeks to 51.782M from 51.799M.","Error stemmed from double-counting of subscribers transitioning between Clinical and other plans; reporting framework revised.","No other financial information, including revenues and EPS, was affected.","FY 2024 guidance reaffirmed: total subscribers 3.8-4.0M, Clinical subscribers 140k-160k, and expectation for subscription revenue growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-135310","json":"https://secwatch.observer/filing/0001193125-24-135310.json","markdown":"https://secwatch.observer/filing/0001193125-24-135310.md","text":"https://secwatch.observer/filing/0001193125-24-135310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105319/000119312524135310/0001193125-24-135310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105319/000119312524135310/d808697d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:41:33.071342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3efff03060bded12014f79b804705e5bea49c5d3","claim":"WW INTERNATIONAL, INC. reported first quarter ended March 30, 2024 results: revenue $206.5 million, net income ($347.9), EPS ($4.39).","evidence_excerpt":"as applicable. No other information was incorrectly presented. • End of Period Subscribers of 4.0 million, including 87 thousand End of Period Clinical Subscribers • Revenues of $206.5 million • Gross margin of 66.7%; excluding the net impact of restructuring charges related to prior year restructuring plans, adjusted gross margin of 67.9% • Operating Loss of $269.3","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105319/000119312524135310/0001193125-24-135310-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 30, 2024"},{"label":"Revenue","value":"$206.5 million"},{"label":"Net income","value":"($347.9)"},{"label":"EPS","value":"($4.39)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}